静脉注射酮咯酸可显著减少腰椎融合术后阿片类药物使用并缩短住院时间:一项随机对照试验
这项随机双盲安慰剂对照试验纳入171例腰椎融合患者,比较静脉注射酮咯酸(IV-K)、静脉注射对乙酰氨基酚(IV-A)与静脉注射安慰剂(IV-P)的术后阿片类药物使用。IV-K组72小时阿片类药物用量低于IV-A组和IV-P组,且术后第1天疼痛评分更低、住院时间更短,阿片相关不良事件无差异。
要点
- IV-K组72小时阿片用量173±157 mg,低于IV-A组255±179 mg和IV-P组299±179 mg(P=0.000)。
- 按意向治疗分析,IV-K在阿片用量上优于IV-A(P=0.025)和IV-P(P=0.000)。
- 与IV-P相比,IV-K组术后第1天最差、最好、平均及当前疼痛评分均显著更低。
核心结论
- 静脉注射酮咯酸通过减少阿片类药物使用、改善术后第1天疼痛控制并缩短住院时间,且不增加并发症或假关节形成,可能成为加速康复外科方案的重要组成部分。
研究设计与样本
- 随机、双盲、安慰剂对照试验,纳入2016年4月至2019年12月期间接受1至2节段腰椎融合术的18至75岁患者,共171例进入意向治疗分析(IV-K组58例、IV-A组55例、IV-P组58例),平均年龄57.1岁。
主要发现
- IV-K组72小时阿片类药物用量为173±157 mg,低于IV-A组的255±179 mg和IV-P组的299±179 mg(P=0.000)。
- 在意向治疗分析中,IV-K组阿片用量优于IV-A组(P=0.025)和IV-P组(P=0.000),但符合方案分析中与IV-A组的差异未达统计学显著(P=0.063)。
- 与IV-P组相比,IV-K组术后第1天最差疼痛评分(P=0.004)、最好疼痛评分(P=0.001)、平均疼痛评分(P=0.001)和当前疼痛评分(P=0.002)均显著更低。
- 在意向治疗分析中,IV-K组住院时间显著短于IV-P组(P=0.009)。
- 阿片相关不良事件、引流量、临床结局、输血率和融合率方面无差异。
临床怎么用
- 作者认为,静脉注射酮咯酸可能成为加速康复外科方案的重要组成部分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: A randomized, double-blinded, placebo-controlled trial. OBJECTIVE: To examine the effect of intravenous ketorolac (IV-K) on hospital opioid use compared with IV-placebo (IV-P) and IV acetaminophen (IV-A). SUMMARY OF BACKGROUND DATA: Controlling postoperative pain while minimizing opioid use after lumbar spinal fusion is an important area of study. PATIENTS AND METHODS: Patients aged 18 to 75 years undergoing 1 to 2 level lumbar fusions between April 2016 and December 2019 were included. Patients with chronic opioid use, smokers, and those on systemic glucocorticoids or contraindications to study medications were excluded. A block randomization scheme was used, and study personnel, hospital staff, and subjects were blinded to the assignment. Patients were randomized postoperatively. The IV-K group received 15 mg (age > 65) or 30 mg (age < 65) every six hours (q6h) for 48 hours, IV-A received 1000 mg q6h, and IV-P received normal saline q6h for 48 hours. Demographic and surgical details, opioid use in morphine milliequivalents, opioid-related adverse events, and length of stay (LOS) were recorded. The primary outcome was in-hospital opioid use up to 72 hours. RESULTS: A total of 171 patients were included (58 IV-K, 55 IV-A, and 58 IV-P) in the intent-to-treat (ITT) analysis, with a mean age of 57.1 years. The IV-K group had lower opioid use at 72 hours (173 ± 157 mg) versus IV-A (255 ± 179 mg) and IV-P (299 ± 179 mg; P = 0.000). In terms of opiate use, IV-K was superior to IV-A ( P = 0.025) and IV-P ( P = 0.000) on ITT analysis, although on per-protocol analysis, the difference with IV-A did not reach significance ( P = 0.063). When compared with IV-P, IV-K patients reported significantly lower worst ( P = 0.004), best ( P = 0.001), average ( P = 0.001), and current pain ( P = 0.002) on postoperative day 1, and significantly shorter LOS ( P = 0.009) on ITT analysis. There were no differences in opioid-related adverse events, drain output, clinical outcomes, transfusion rates, or fusion rates. CONCLUSIONS: By reducing opioid use, improving pain control on postoperative day 1, and decreasing LOS without increases in complications or pseudarthrosis, IV-K may be an important component of "enhanced recovery after surgery" protocols.
引用
- Iyer S, Steinhaus ME, Kazarian GS, et al. Intravenous Ketorolac Substantially Reduces Opioid Use and Length of Stay After Lumbar Fusion: A Randomized Controlled Trial. Spine (Phila Pa 1976). 2023. PMID: 37737686. doi:10.1097/BRS.0000000000004831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。